This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Souid, A.-K. Articles by Bernstein, M. L. Search for Related Content PubMed PubMed Citation Articles by Souid, A.-K. Articles by Bernstein, M. L.

Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors¹

Departments of Pediatric Hematology/Oncology, State University of New York Upstate Medical University, Syracuse, New York 13210 [A-K. S., R. L. D.]; Texas Children’s Cancer Center, Houston, Texas 77030 [S. M. B.]; Sainte-Justine Hospital, H3T 1C5, Canada [L. H., M. L. B.]; and the Statistical Office, Children Oncology Group, Gainesville, Florida 32601 [J. S., W. D. M.]

Purpose: This Phase I study was designed primarily to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of irinotecan and cisplatin with and without amifostine in children with refractory solid tumors.

Patients and methods: Cisplatin, at a fixed dose of 30 mg/m², and escalating doses of irinotecan (starting dose, 40 mg/m²) were administered weekly for four consecutive weeks, every 6 weeks. After the MTD of irinotecan plus cisplatin was determined, additional cohorts of patients were enrolled with amifostine (825 mg/m²) support. Leukocyte DNA-platinum adducts and pharmacokinetics of cisplatin and WR-1065 (amifostine-active metabolite) were also determined.

Results: Twenty-four patients received 43 courses of therapy. The MTD for irinotecan administered in combination with cisplatin (30 mg/m²) was 50 mg/m². The DLTs of this combination were neutropenia and thrombocytopenia. With the addition of amifostine, at an irinotecan dose of 65 mg/m² and cisplatin dose of 30 mg/m², the DLT was hypocalcemia. Although no objective responses were observed, six patients received at least three courses of therapy. The amounts of platinum adducts (mean ± SD) were 10 ± 20 molecules/10⁶ nucleotides. The maximum plasma concentrations (C_max) for free cisplatin and WR-1065 were 4.5 ± 1.6 µM and 89 ± 10 µM, respectively. The half-life (t_1/2) for free plasma cisplatin was 25.4 ± 5.4 min. The initial t_1/2 for plasma WR-1065 was 7 min and terminal t_1/2 24 min.

Conclusion: The combination of cisplatin and irinotecan administered weekly for 4 weeks in children with refractory cancer is well tolerated. Amifostine offers some myeloprotection, likely permitting 30% dose escalation for irinotecan, when administered in a combination regimen with cisplatin. However, effective antiemetics and calcium supplementation are necessary with the use of amifostine. Further escalation of irinotecan dosing, using these precautions for amifostine administration, may be possible.

This article has been cited by other articles:

				J. Mora, O. Cruz, S. Gala, and R. Navarro Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin Neuro-oncol, January 1, 2007; 9(1): 39 - 46. [Abstract] [Full Text] [PDF]

				J. Goodisman and A.-K. Souid Constancy in integrated Cisplatin plasma concentrations among pediatric patients. J. Clin. Pharmacol., April 1, 2006; 46(4): 443 - 448. [Abstract] [Full Text] [PDF]

				D. Hagrman, J. Goodisman, and A.-K. Souid Kinetic Study on the Reactions of Platinum Drugs with Glutathione J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 658 - 666. [Abstract] [Full Text] [PDF]

				D. Hagrman, J. Goodisman, J. C. Dabrowiak, and A.-K. Souid KINETIC STUDY ON THE REACTION OF CISPLATIN WITH METALLOTHIONEIN Drug Metab. Dispos., July 1, 2003; 31(7): 916 - 923. [Abstract] [Full Text] [PDF]